Journal of Dermatology最新文献

{"title":"Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes","authors":"Takamichi Kitano,&nbsp;Toshikazu Koiwai,&nbsp;Koki Fujikawa,&nbsp;Sachi Mori,&nbsp;Tatsumi Matsumoto,&nbsp;Takashi Sato","doi":"10.1111/1346-8138.17409","DOIUrl":"10.1111/1346-8138.17409","url":null,"abstract":"<p>Acne vulgaris is a complex condition involving factors that affect the pilosebaceous unit. A primary manifestation of acne pathology is the development of comedones, often linked to the overproduction of sebum resulting from 5α-dihydrotestosterone (5α-DHT) and insulin activity. Ozenoxacin is a topical quinolone that exhibits potent antibacterial activity against <i>Cutibacterium acnes</i> (<i>C. acnes</i>). It is commonly used to treat acne associated with this bacterium; however, its effect on sebum production within the sebaceous glands remains unclear. In this study, the effects of ozenoxacin on sebum production were examined using insulin- and 5α-DHT-differentiated hamster sebocytes. Ozenoxacin showed a dose-dependent inhibition of lipid droplet formation and triacylglycerol (TG) production, which is a major component of sebum. In addition, it suppressed the expression of diacylglycerol acyltransferase 1, stearoyl-CoA desaturase-1, and perilipin-1 mRNA, all important factors involved in sebum synthesis, in a dose-dependent manner. Moreover, ozenoxacin decreased phosphorylated 40S ribosomal protein S6 levels downstream of the mechanistic/mammalian target of rapamycin complex 1 (mTORC1), without altering the phosphorylation of Akt, an upstream regulator of mTORC1, in both insulin- and 5α-DHT-treated hamster sebocytes. Interestingly, nadifloxacin, but not clindamycin, exhibited a similar suppression of sebum production, albeit with lesser potency compared with ozenoxacin. Furthermore, a topical application of a 2% ozenoxacin-containing lotion to the auricle skin of hamsters did not affect the size of the sebaceous glands or epidermal thickness. Notably, it decreased the amount of TG on the skin surface. The results provide novel insights into the sebum-inhibitory properties of ozenoxacin, indicating its potential efficacy in controlling microbial growth and regulating sebum production for acne management.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1187-1198"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variants in the L12 linker domain of KRT10 are causal to atypical epidermolytic ichthyosis","authors":"J. J. A. J. van der Velden,&nbsp;M. W. van Gisbergen,&nbsp;M. A. F. Kamps,&nbsp;R. Janssen,&nbsp;G. F. H. Diercks,&nbsp;P. M. Steijlen,&nbsp;M. van Geel,&nbsp;M. C. Bolling","doi":"10.1111/1346-8138.17395","DOIUrl":"10.1111/1346-8138.17395","url":null,"abstract":"<p>Epidermolytic ichthyosis (EI) is a type of congenital ichthyosis, characterized by erythema and blistering at birth followed by hyperkeratosis. EI is caused by pathogenic variants in the genes <i>KRT1</i> and <i>KRT10</i>, encoding the proteins keratin 1 (KRT1) and keratin 10 (KRT10), respectively, and is primarily transmitted by autosomal-dominant inheritance, although recessive inheritance caused by nonsense variants in <i>KRT10</i> is also described. The keratins form a network of intermediate filaments and are a structural component of the cytoskeleton, giving strength and resilience to the skin. We present three cases of mild EI caused by pathogenic KRT10 variations in the L12 linker domain. To our knowledge, this is the first time L12 linker domain pathogenic variants are identified in <i>KRT10</i> for EI. The aim of this study was to identify gene variants for patients with EI in <i>KRT1</i> or <i>KRT10</i>. To establish the pathogenicity of the found variations in <i>KRT10</i>, we evaluated all patients and available family members clinically. Genetic analyses were performed using Sanger sequencing. Vectors containing wild-type or mutated forms of <i>KRT10</i> were transfected into HaCaT cells and analyzed by high-resolution confocal microscopy. Genetic analysis of <i>KRT10</i> identified a heterozygous de novo variant c.910G&gt;A p.(Val304Met) in family 1, a familial heterozygous variant c.911T&gt;C p.(Val304Ala) in family 2, and a familial heterozygous variant c.917T&gt;C p.(Met306Thr) in family 3. All identified missense variants were located in the L12 linker domain of KRT10. In vitro study of aggregate formation of the missense variants in KRT10 only showed a very mild and not quantifiable aggregate formation in the KRT10 network, compared with the wild-type sequence. We report three different novel missense variants in the L12 linker domain of KRT10 in patients with an atypical, milder form of EI resembling peeling skin syndrome.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1180-1186"},"PeriodicalIF":2.9,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mosaic KRAS mutations cause an atypical variant of phacomatosis spilosebacea","authors":"Daniele Torchia","doi":"10.1111/1346-8138.17404","DOIUrl":"10.1111/1346-8138.17404","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1262-1263"},"PeriodicalIF":2.9,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141772283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic profiles of Merkel cell carcinoma in Japan","authors":"Junji Kato,&nbsp;Tokimasa Hida,&nbsp;Masashi Idogawa,&nbsp;Takashi Tokino,&nbsp;Hisashi Uhara","doi":"10.1111/1346-8138.17401","DOIUrl":"10.1111/1346-8138.17401","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1259-1261"},"PeriodicalIF":2.9,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database","authors":"Anwar Al Hammadi,&nbsp;Nisha V. Parmar,&nbsp;Mohamed Farghaly,&nbsp;Sara Al Dallal,&nbsp;Mostafa Wagdy Abdullah Zayed,&nbsp;Fadwa Ebeid,&nbsp;Kumaresan Subramanyam,&nbsp;Badarinath Chickballapur Ramachandrachar,&nbsp;Haytham Mohamed Ahmed","doi":"10.1111/1346-8138.17381","DOIUrl":"10.1111/1346-8138.17381","url":null,"abstract":"<p>Alopecia areata (AA) is an autoimmune disorder that manifests as nonscarring hair loss and imposes a substantial disease burden. The current study, using an e-claims database, assesses the disease burden, comorbidities, treatment patterns, specialties involved in the diagnosis of AA, healthcare resource utilization (HCRU), and associated costs in privately insured patients with AA in Dubai, United Arab Emirates. The retrospective longitudinal secondary study was conducted using Dubai Real-World Database e-claims data during 01 January 2014 to 30 June 2022. Patients with at least one diagnosis claim of AA during the index period (01 January 2015–30 June 2021) with continuous enrollment (one or more AA/non-AA claim in the post-index period) were included in the analysis. The patients were stratified into subcohorts based on diagnosis code and treatment patterns, as mild, <b>moderate-to-severe</b>, and others. Demographics, comorbidities, treatment patterns, specialists visited, and HCRU were assessed. The study included 11 851 patients with AA (mean age: mild: 37 years; <b>moderate-to-severe</b>: 36 years), with a male predominance (mild: 77.6%; <b>moderate-to-severe</b>: 60.8%). The most prevalent comorbidities in the moderate-to-severe AA subcohort were autoimmune and T-helper 2–mediated immune disorders, including contact dermatitis and eczema (62.1%), atopic dermatitis (36.1%), and asthma (36.1%). Most patients consulted dermatologists for treatment advice (mild AA: 87.4%; moderate-to-severe AA: 47.7%) and, notably, within 1 day of AA diagnosis. Topical steroids were frequently prescribed across cohorts, regardless of disease severity. Analysis of comorbidities among patients with AA indicated an additional HCRU burden among these subsets of patients. The median disease-specific HCRU cost was higher for psychological comorbidities versus autoimmune and T-helper 2–mediated immune disorders (US $224.99 vs US $103.70). There is a substantial disease and economic burden in patients with AA and associated comorbid conditions; therefore, investing in novel therapies that target the underlying autoimmune pathway may address the gap in effective management of AA.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1157-1171"},"PeriodicalIF":2.9,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17381","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An exploratory study of the efficacy and safety of amenamevir for the treatment of herpes zoster in patients receiving immunosuppressive drugs","authors":"Shinichi Imafuku,&nbsp;Satoshi Takeuchi,&nbsp;Kazunori Urabe,&nbsp;Masataka Arakawa,&nbsp;Ryo Sasaki,&nbsp;Daigo Oka,&nbsp;Takenobu Yamamoto,&nbsp;Fumitake Ono,&nbsp;Shigeho Shirahama,&nbsp;Shinichiro Yasumoto,&nbsp;Hiroaki Fukuda","doi":"10.1111/1346-8138.17364","DOIUrl":"10.1111/1346-8138.17364","url":null,"abstract":"<p>Amenamevir is an oral once-daily antiherpesvirus drug that can be administered without dose adjustment in patients with impaired renal function. There are currently no clinical data on immunocompromised patients with herpes zoster treated with amenamevir. Therefore, an exploratory study of the efficacy and safety of amenamevir against herpes zoster in patients with immunosuppression was conducted. Inclusion criteria included patients with acute herpes zoster receiving immunosuppressive drugs or those with malignant tumors or autoimmune diseases. Twenty-four patients were included and received amenamevir (400 mg once daily after meals) for up to 14 days. The primary end point of overall improvement in skin symptoms 7 days after treatment initiation (day 7) was 58.3% for “markedly improved” and 20.8% for “improved.” The combined improvement rate was 79.2% (95% confidence interval, 57.8–92.9), and 20.8% of patients experienced “worsened” symptoms. The secondary end points of overall improvement in skin symptoms on day 14 and day 28 were 95.7% and 100%, respectively. The skin symptoms progressed during treatment, peaking on day 7, and then began to heal. By Kaplan–Meier estimation, the median periods to complete crusting and healing were both day 14. There were five adverse events with a possible causal relationship to amenamevir (bacterial skin infection, anemia, hyponatremia, headache, and abnormal liver function) in one of the 24 patients. Although the bacterial skin infection was severe, all events in this patient were reported to be either recovered or recovering. These findings indicate that amenamevir can be effective and safe in immunocompromised patients with herpes zoster. However, as worsening can happen around day 7, it is necessary to carefully monitor such patients and switch to other therapies such as intravenous acyclovir if necessary.</p><p><b>Clinical trial identifier</b>: Japan Registry of Clinical Trials jRCTs031190208.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"1279-1289"},"PeriodicalIF":2.9,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17364","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type: A case series and review of the literature","authors":"Manuel Winkler,&nbsp;Jana Dorothea Albrecht,&nbsp;Christian Sauer,&nbsp;Theresa Kordaß,&nbsp;Emmanuella Guenova,&nbsp;Elisabeth Livingstone,&nbsp;Marion Wobser,&nbsp;Christina Mitteldorf,&nbsp;Cyrill Géraud,&nbsp;Jan Peter Nicolay","doi":"10.1111/1346-8138.17339","DOIUrl":"10.1111/1346-8138.17339","url":null,"abstract":"<p>Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is a subtype of cutaneous B-cell lymphoma with unfavorable prognosis usually requiring aggressive polychemotherapy for disease control. Only single cases of spontaneous regression of PCDLBCL, LT are reported in the literature, peaking 3 months post-biopsy following a clinical history of no longer than 1 year. Here, we report the first case of a spontaneously relapsing and remitting PCDLBCL, LT with complete regression after a clinical history of more than 9 years and thus an atypically indolent clinical course. The female patient presented with recurrent erythematous, non-ulcerated, non-raised plaques of the right lower leg for 6 years. Pathological workup and exclusion of a systemic disease confirmed the diagnosis of PCDLBCL, LT. Due to the history of repeated spontaneous remission, no therapy was initiated. Nine years after first occurrence the patient presented with complete clinical remission lasting for 64 months. We retrospectively identified four additional PCDLBCL, LT patients with spontaneous remission lasting up to 53 months. Our data provide evidence for a distinct PCDLBCL, LT patient subgroup that clinicians should be aware of and warrants a watch-and-wait treatment regime.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1233-1239"},"PeriodicalIF":2.9,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A double-blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis","authors":"Jingjing Chen,&nbsp;Yijin Luo,&nbsp;Yuanyuan Duan,&nbsp;Liangchun Wang,&nbsp;Hai Long,&nbsp;Yi Liu,&nbsp;Xu Yao,&nbsp;Qianjin Lu","doi":"10.1111/1346-8138.17354","DOIUrl":"10.1111/1346-8138.17354","url":null,"abstract":"<p>Lupus erythematosus panniculitis (LEP) is a chronic inflammatory skin disease with a significant impact on the overall well-being of patients. The safety and efficacy of oral baricitinib for the treatment of LEP have not been studied. This study aimed to explore the efficacy of oral baricitinib in patients with LEP who are recalcitrant or intolerant to conventional therapies. Patients (aged ≥18 years) with active LEP (with a revised cutaneous lupus erythematosus disease area and severity index [RCLASI]-active score ≥4] were randomly assigned 2:1 to baricitinib (4 mg) or placebo (once daily for 20 weeks). The placebo group was switched to baricitinib (4 mg) at week 13, and the final evaluation was conducted at week 24. The primary endpoint was the proportion of patients with an RCLASI-A score decreased by 20% at week 12. The secondary endpoints included the changes in the Cutaneous Lupus Erythematosus Disease Area and Severity Index active-(CLASI-A) score, the Dermatology Life Quality Index (DLQI), the Physician's Global Assessment (PGA) score, and safety. Five patients were enrolled. Three patients received baricitinib (4 mg), and two patients were treated with placebo. Two patients in the baricitinib treatment group showed a significant RCLASI-A decrease at week 12 and week 24. Two patients in the placebo group had no change in RCLASI-A at week 12 and a significant decrease at week 24. No new safety events were observed. Treatment with baricitinib was effective and well tolerated in patients with LEP.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"1434-1440"},"PeriodicalIF":2.9,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Buruli ulcer with satellite lesions: A case report from Japan","authors":"Ryo Fukaura,&nbsp;Haruka Koizumi,&nbsp;Norika Akashi,&nbsp;Satoko Imai,&nbsp;Chiaki Murase,&nbsp;Yuji Miyamoto,&nbsp;Norihisa Ishii,&nbsp;Rie Yotsu,&nbsp;Yoshinao Muro,&nbsp;Masashi Akiyama","doi":"10.1111/1346-8138.17274","DOIUrl":"10.1111/1346-8138.17274","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"e360-e362"},"PeriodicalIF":2.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terbinafine-resistant tinea pedis and tinea unguium in Japanese military personnel","authors":"Sara Higuchi,&nbsp;Hiromitsu Noguchi,&nbsp;Tadahiko Matsumoto,&nbsp;Honoka Nojo,&nbsp;Rui Kano","doi":"10.1111/1346-8138.17389","DOIUrl":"10.1111/1346-8138.17389","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 9","pages":"1256-1258"},"PeriodicalIF":2.9,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}